MedTrace Logo

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

NCT05540665 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-03-24

Study results available
· View outcomes & findings →

Summary

Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).

Conditions

Interventions

DRUG

Daxdilimab

Daxdilimab will be administered subcutaneously as two injections for each dose. Other Names: HZN-7734

DRUG

Daxdilimab

Daxdilimab will be administered subcutaneously as two injections for each dose. Other Names: HZN-7734

DRUG

Placebo (Normal Saline)

Placebo will be administered subcutaneously as two injections for each dose.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-26
Primary Completion
2024-01-04
Completion
2024-01-04
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Croatia
  • Israel
  • Malaysia
  • Philippines
  • Poland
  • Serbia
  • Spain
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05540665 on ClinicalTrials.gov